This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Deciphera Pharmaceuticals, LLC. Active years: 2016.
Company Filing History:
Years Active: 2016
Title: The Innovative Contributions of Marc Rudoltz
Introduction
Marc Rudoltz is a notable inventor based in West Orange, NJ (US). He has made significant contributions to the field of cancer treatment through his innovative research and development. His work focuses on methods for inhibiting TIE2 kinase, which plays a crucial role in tumor growth and metastasis.
Latest Patents
Marc Rudoltz holds a patent for "Methods for inhibiting tie-2 kinase useful in the treatment of cancer." This invention relates to methods of inhibiting TIE2 kinase, which is useful in addressing tumor growth, invasiveness, intravasation, dissemination, metastasis, and immunosuppression. Specifically, the invention utilizes 1-(3-tert-butyl-1-(quinolin-6-yl)-1H-pyrazol-5-yl)-3-(2-fluoro-4-(2-(methylcarbamoyl)pyridin-4-yloxy)phenyl)urea and its salts, as described in the patent.
Career Highlights
Marc Rudoltz is currently associated with Deciphera Pharmaceuticals, LLC, where he continues to advance his research in cancer therapies. His dedication to innovation in this critical field has positioned him as a valuable contributor to medical science.
Collaborations
Some of his notable coworkers include Daniel L Flynn and Michael D Kaufman, who collaborate with him in various research initiatives.
Conclusion
Marc Rudoltz's work exemplifies the impact of innovative thinking in the medical field, particularly in cancer treatment. His patent and ongoing research contribute significantly to the fight against cancer, showcasing the importance of innovation in healthcare.